Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Myrexis, Inc.
A market leader in opioid addiction, Indivior is expanding into the cannabis abuse space which is increasing exponentially due to widespread legalization of recreational use for the drug.
Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.
Private Company Edition: More $100m-plus mega-rounds means another billion-dollar week for venture capital deals, including financings for G2 Bio, Hummingbird and Numab. Also, BioTheryX brings in $92m, Vedere launches with $77m and Eliem raises $60m two months after launching with $80m.
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
- Other Names / Subsidiaries
- Myriad Pharmaceuticals, Inc.